OS Therapies Inc. (OSTX) - 10-K Filing Summary
Business Context and Reporting Period
Company: OS Therapies Inc.
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: OS Therapies is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma (OS) and other solid tumors. The company operates as a single segment and is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Assets: The pipeline centers on two technologies: (1) OST-HER2, a genetically engineered Listeria monocytogenes immunotherapy for Osteosarcoma (Phase IIb), and (2) OST-tADC, a tunable antibody-drug conjugate platform currently in preclinical development.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Total Operating Expenses | $6,814 | $4,343 |
| Net Loss | $(8,883) | $(7,792) |
| Cash and Cash Equivalents (Year End) | $5,534 | $39 |
| Net Cash Used in Operating Activities | $(7,282) | $(3,007) |
| Net Cash Provided by Financing Activities | $12,777 | $2,873 |
| Accumulated Deficit | $(40,404) | $(29,518) |
Liquidity: As of December 31, 2024, the company held approximately $5.5 million in cash. Management estimates this, combined with recent financing, will fund operations for the next 9 to 12 months. The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and a net capital deficiency.
Material Changes vs. Prior Period
- Operating Expenses: Increased by approximately $2.5 million (57%) from 2023 to 2024. This was driven primarily by a $2.85 million increase in General and Administrative (G&A) expenses due to increased consultant payments, payroll, and legal fees associated with public company compliance. Research and Development (R&D) expenses decreased by $0.38 million, largely due to reduced vendor expenses for the OST-tADC program.
- Capital Structure: In August 2024, the company completed its Initial Public Offering (IPO), raising $6.4 million in gross proceeds. All outstanding convertible notes (Groups A through F) were converted into common stock upon the IPO closing.
- Private Placement: In late 2024 and early 2025, the company executed a Private Placement raising approximately $7.1 million in gross proceeds through the issuance of Series A Senior Convertible Preferred Stock and warrants.
- Debt: Interest expense decreased from $3.45 million in 2023 to $2.05 million in 2024, reflecting the conversion of convertible debt to equity during the IPO.
Guidance, Outlook, and Management Commentary
- Clinical Milestone: On January 15, 2025, the company announced its Phase IIb clinical trial for OST-HER2 achieved its primary endpoint with statistical significance. The trial showed 33% of treated patients were event-free at 12 months compared to 20% in the historical control group. No Grade 5 (death) adverse events were observed.
- Regulatory Path: Management plans to request a Type B or Type C FDA meeting in Q1 2025 to discuss the data and the path to a Biologics License Application (BLA). Subject to positive feedback, a BLA submission is targeted for Q2 2025. The company believes a Phase III trial may not be necessary pending FDA determination.
- Acquisition: On January 28, 2025, OS Therapies entered into an agreement to acquire HER2 and Listeria monocytogenes-related assets from Ayala Pharmaceuticals (formerly Advaxis) for $8 million ($0.5 million cash + $7.5 million in stock). This includes IND filings for non-small cell lung cancer and prostate cancer.
- Outlook: The company expects to incur significant operating losses for the foreseeable future as it advances clinical trials and prepares for potential commercialization. It anticipates increased expenses related to R&D, regulatory compliance, and public company operations.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to raise additional capital beyond the current 9-12 month runway, given the auditor's "substantial doubt" qualification.
- Regulatory Approval: Monitor the outcome of the planned FDA Type B/C meeting in Q1 2025 and the subsequent BLA submission timeline. Confirm whether the FDA requires a Phase III trial.
- Dilution Risk: Assess the impact of the recent Private Placement (Series A Preferred Stock and Warrants) and the pending Ayala acquisition (stock consideration) on existing shareholders.
- Internal Controls: Note that management concluded internal controls over financial reporting were not effective as of December 31, 2024, due to inadequate segregation of duties and insufficient written policies.
- Intellectual Property: Confirm the status of the license assignment from Ayala to the University of Pennsylvania, which is a closing condition for the asset acquisition.